

Area Prescribing Committee Oxfordshire – 13th May 2014

Bullet Points approved by Clinical Ratification Group 5th June 2014:

- 1. Milk Formulae** Following the agreed Cow's Milk Protein Allergy (CMPA) guidance there has been communication from GPs requesting clarification on whether milk products should be prescribed or whether parents should be advised to purchase. It has been suggested that there should be a limit on what should be prescribed. The committee agreed that following a review of other CCG policies a proposal should be submitted restricting milk formulae prescribing. It was initially suggested that the prescribing should be limited to a short period with follow on supplies being purchased. It was felt that this would require a public consultation process similar to that followed with implementation of gluten free prescribing policy. This will be submitted to the next committee in July.
- 2. Relvar Ellipta.** Following the agreement at a previous meeting that this product would be placed on the BLACK list there has been a specific request for use in poorly controlled, non-compliant teenage asthmatic patients. Although the efficacy evidence does not represent any advantage over existing products it has a once daily dosing schedule and so may have an advantage of compliance in this group of patients. It was therefore agreed for patients that are currently under specialist care and at stage 5 of the BTS guidelines. The requesting consultant Jeremy Hull will be requested to review and feedback on the success in this patient group. **Agreed for specific patient group**
- 3. Modafinil** A request had been received from MMTC for Modafinil for the treatment of excessive day time sleepiness in myotonic dystrophy. An EMA safety guidance highlighting the risks recommends that the benefits of modafinil only outweigh the risks in the treatment of narcolepsy. In addition this is an expensive treatment at over £200 per month. The committee did not agree to GP prescribing in this indication which is outside of the safety guidance. In addition it was agreed that the current use of modafinil should be reviewed. It is currently traffic lighted as yellow following initiation by a consultant specialist for sleep disorders. **Not agreed and review current use.**
- 4. Vitamin D** Guidelines for Vitamin D monitoring and treatment were agreed. These highlight when to test Vitamin D levels and what action to take. **Guideline Agreed**
- 5. Denosumab First Dose** It was agreed in principle that Denosumab could be initiated in primary care. Continuation treatment is currently undertaken in primary care. There were a number of comments and amendments agreed to the proposed guidance and this will be updated by OUH. Primary care initiation can commence when the updated guidance is received and transfer of funding has been agreed. **Agreed-awaiting guidance update and funding**
- 6. Nalmefene** It was agreed that this should remain on the holding list until the commissioners of alcohol withdrawal services have provided an update and NICE guidance is produced. **Remain on Holding List**
- 7. Diabetic Needles** It was agreed that GlucoRx finepoint needles should be prescribed in place of BD Micro-Fine/Ultraneedles. This has been agreed with the community diabetic service and OCDEM. There are no clinical concerns and the switch would produce a saving of approximately £125,000. **Agreed Switch**
- 8. Alogliptin** This drug has considerable cost advantage over other gliptins and was agreed for new patients. Switching patients from other gliptins was discussed and it was felt that some additional

guidance to review current patients for appropriateness of gliptin use was needed. **Agreed as first line gliptin with additional guidance on place of gliptin therapy.**

- 9. Antihistamines** It was agreed to update the traffic light classification removing existing restrictions on antihistamines as minimal price differential and to reinforce the message that these can be purchased. It was agreed to review the use of Fexofenadine as this has the disadvantage of being the only product that cannot be purchased over the counter. **Agreed to update traffic light**

Summary of Traffic Light Classifications:

Jane Lynch May 2014

TRAFFIC LIGHT UPDATE:-		
Relvar Ellipta	Yellow	For non-compliant, poorly controlled teenage asthmatic at stage 5 of BTS.
All antihistamines except Fexofenadine	Green	Recommend patients purchase
Denosumab first dose	Green	Subject to amended guidelines
Rivaroxaban Dabagatran Apixaban for AF	Brown	In line with NICE and local guidelines (to be updated)
Dalteparin for intermediate risk pregnancy	Yellow	In line with new Dalteparin guidelines
Tadalafil	Black	Pre and post radical prostatectomy-not on OUH formulary for this indication
sulfamethoxypyridazine for pemphigoid	Black	Hospital only drug-not on OUH formulary
iAluRil	Black	Specialist treatment-not on OUH formulary
Lomitapide	Black	New treatment for Homozygous, familial hypercholesterolaemia Specialised commissioning/not routinely commissioned
Alogliptin	Green	First line as cheapest gliptin available
Zuclopenthixol Acetate	Red	To be used under the direction of consultant psychiatrist
Modafinil for excessive daytime sleepiness in myotopic dystrophy	Red	In line with EMA safety guidance
Holding List		
Nalmefene	Holding List	Awaiting discussion with Public Health
Rivaroxiban for ACS	Holding List	2.5mg tablets not yet available
Alprostadil topical	Holding List	Not yet available